Cemiplimab + Fianlimab for Head and Neck Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
The goal of this clinical trial is to learn if the combination of cemiplimab and fianlimab can improve outcomes compared to cemiplimab alone in adults with Human Papillomavirus Positive HPV-positive head and neck cancer.
Who Is on the Research Team?
Ari arirosenberg@bsd.uchicago.edu
Principal Investigator
University of Chicago
Are You a Good Fit for This Trial?
Adults with advanced HPV-positive head and neck cancer who haven't had treatment yet. They should have a specific stage of tumor growth, no prior radiation or chemo for this cancer, and measurable disease. Surgery is okay if there's still some disease left. Participants need to be over 18 with good performance status and organ function.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Induction Treatment
Participants receive Cemiplimab in combination with chemotherapy (paclitaxel and carboplatin) for 3 cycles
Chemoradiation
Participants undergo chemoradiation with Cisplatin and Radiotherapy
Maintenance Treatment
Cemiplimab is administered for an additional 6 months
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Cemiplimab
- Fianlimab
Trial Overview
The trial tests if adding fianlimab to cemiplimab improves outcomes compared to just cemiplimab in treating head and neck cancer. It involves patients receiving radiation, carboplatin, paclitaxel along with the study drugs.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Participants assigned to this arm will receive Cemiplimab and Fianlimab in combination with chemotherapy (paclitaxel and carboplatin) for 3 cycles (9 weeks). This will be followed by Chemoradiation with Cisplatin and Radiotherapy for 7 weeks. Cemiplimab will then be given for an additional 6 months.
Participants assigned to this arm will receive Cemiplimab in combination with chemotherapy (paclitaxel and carboplatin) for 3 cycles (9 weeks). This will be followed by Chemoradiation with Cisplatin and Radiotherapy for 7 weeks. Cemiplimab will then be given for an additional 6 months.
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Chicago
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.